Onvansertib (NMS-P937, PCM-075, NMS1286937)是一种口服有效的，选择性的 Polo-like Kinase 1 (PLK1) 抑制剂,其IC50值为2 nM，比PLK2/PLK3高出5000倍的选择性。Onvansertib (NMS-P937) 可在肿瘤细胞系中造成有丝分裂周期阻滞及凋亡并抑制肿瘤生长。 Information Onvansertib (NMS-P937, PCM-075, NMS1286937) is an orally available, selectivePolo-like Kinase 1 (PLK1)inhibitor withIC50of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed byapoptosisin cancer cell lines and inhibits tumor growth. Phase 1. Targets PLK1 2 nM In vitro NMS-P937 shows a broad-spectrum antiproliferative activity against different solid tumor, leukemias and lymphomas cell lines. NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in A2780 cells. In vivo In mice xenografted with human HCT116 colon adenocarcinoma cells, NMS-P937 (90 mg/kg/d i.v. or p.o.) shows a significant tumor growth inhibition. In mice bearing HT29, Colo205 colorectal, or A2780 ovarian xenograft tumors, NMS-P937 inhibits xenograft tumor growth. In addition, NMS-P937, in combination with approved cytotoxic drugs, causes enhanced tumor regression, and prolongs survival of animals. Cell Research(from reference) Cell lines：137 solid tumor cell lines, and 43 cell lines derived from leukemias and lymphomas Concentrations：~10 μM Incubation Time：72 hours